Developer docs
API playgroundTry for free, no card

Search company profiles

Pelage Pharmaceuticals

Full company profile

uuid0000aix

Namestring
Pelage Pharmaceuticals
Legal namestring
Pelage Pharmaceuticals, Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Pelage Pharmaceuticals, Inc. is a privately held, clinical-stage regenerative medicine biotechnology company founded in 2018 and headquartered in Los Angeles, California. The company is developing PP405, a topical small-molecule mitochondrial pyruvate carrier (MPC) inhibitor designed to reactivate dormant hair follicle stem cells (HFSCs) by inhibiting pyruvate oxidation and upregulating lactate dehydrogenase (LDH), thereby restoring the natural hair follicle growth cycle. The technology is rooted in a metabolic switch discovery made by UCLA scientists and is exclusively licensed from the UCLA Technology Development Group.

The company's lead clinical program targets androgenetic alopecia (pattern hair loss), with potential pipeline expansion into chemotherapy-induced alopecia and telogen effluvium. PP405 has completed a Phase 2a randomized placebo-controlled trial in 78 men and women with androgenetic alopecia, meeting its primary safety endpoint with no systemic absorption detected in blood; 31% of men with higher hair loss achieved a >20% increase in hair density at Week 8 versus 0% on placebo, and the program is advancing into Phase 3 trials planned for 2026. The trial design and intended label are explicitly inclusive, targeting all genders, skin phototypes, and hair types.

Pelage is pre-revenue and funded by venture capital, having raised approximately $150.75 million across a Series A (Feb 2024), Series A-1 (Aug 2024), and Series B (Oct 2025), with the Series B co-led by ARCH Venture Partners and GV (Google Ventures). The business model anticipates future revenue from FDA-approved prescription drug commercialization via direct physician-targeted sales or licensing/partnership with a larger pharmaceutical company. Leadership includes a scientific founding team from UCLA, a Clinical Advisory Board of leading academic dermatologists, and an investor-anchored board with deep biotech operating and capital markets experience.

Short descriptiontext

Pelage Pharmaceuticals is a clinical-stage regenerative medicine biotech developing PP405, a topical small-molecule MPC inhibitor that reactivates dormant hair follicle stem cells, for men and women with androgenetic alopecia and related forms of hair loss.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine biotechnology, hair loss therapeutics, topical small molecule, stem cell activation, clinical-stage drug development
Industry2 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Regenerative Hair Loss Therapeutics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-revenue clinical-stage drug development
TypeLicensing Royalties
Description

Currently pre-revenue; the company is a clinical-stage biotech developing its lead asset PP405 through Phase 2a with Phase 3 trials planned for 2026. No commercial product on market. Future revenue expected from FDA-approved prescription drug commercialization (direct sales or partnership licensing).

pelagepharma.com
2Equity financing (venture capital)
TypeSubscription Recurring
Description

Funded through successive venture capital rounds: $16.75M Series A (Feb 2024), $14M Series A-1 (Aug 2024), and $120M Series B (Oct 2025) — totaling approximately $150.75M raised from GV (Google Ventures), ARCH Venture Partners, Main Street Advisors, Visionary Ventures, and YK Bioventures.

pelagepharma.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Pricing details1 tier
1Investigational drug — no commercial pricing available
ModelOtherBilling cadencePay-as-you-go
Notes

PP405 is currently in Phase 2 clinical trials and has not yet been approved by the FDA for commercial sale. Pricing not publicly disclosed.

pelagepharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PP405
Description

Pelage's lead investigational product: a novel, non-invasive, topical small molecule (mitochondrial pyruvate carrier / MPC inhibitor) designed to reactivate dormant hair follicle stem cells and restart hair growth in androgenetic alopecia and other forms of alopecia.

pelagepharma.com
Core offering1 text field

Pelage Pharmaceuticals is developing PP405, a novel, non-invasive, topical small-molecule drug that acts as a mitochondrial pyruvate carrier (MPC) inhibitor to reactivate dormant hair follicle stem cells and stimulate hair regrowth. The investigational product is being advanced through FDA-regulated clinical trials as a first-in-class regenerative treatment for androgenetic alopecia (pattern hair loss), with potential expansion into chemotherapy-induced alopecia and telogen effluvium. The company is currently pre-revenue, with Phase 2a complete and Phase 3 trials planned for 2026, and intends to commercialize via direct physician-targeted sales or partnership with a larger pharmaceutical company.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 31% of men with higher hair loss achieved >20% increase in hair density at Week 8 (vs. 0% in placebo group) after only 4 weeks of topical PP405 dosing
+3 more records
Product overview1 text field

Pelage Pharmaceuticals is a clinical-stage regenerative medicine biotechnology company offering a single unified investigational product platform centered on its lead program PP405. The PP405 platform is a non-invasive, topical small molecule drug designed to reactivate dormant hair follicle stem cells and restore the body's natural ability to grow hair. PP405 acts as a mitochondrial pyruvate carrier (MPC) inhibitor, upregulating lactate dehydrogenase (LDH) to drive stem cell activation and follicular regeneration. It is being developed as a first-in-class treatment for androgenetic alopecia (pattern hair loss) and potentially other forms of hair loss including drug-induced alopecia and telogen effluvium. The technology is rooted in pioneering stem cell research out of UCLA (licensed in 2018) and is delivered as a once-daily topical application without detectable systemic exposure. Pelage is currently advancing PP405 through Phase 2a clinical trials with plans to initiate Phase 3 studies in 2026. The product is targeted at men and women of all skin types and hair types.

Product and service1 record
1PP405
CategoryCore product / Lead investigational drug (regenerative dermatology)
Description

PP405 is a novel, non-invasive, topical small-molecule drug (mitochondrial pyruvate carrier / MPC inhibitor) designed to reactivate dormant hair follicle stem cells and restart hair growth. It acts on the cellular metabolic pathway to upregulate lactate dehydrogenase (LDH), which stem cells are particularly sensitive to, resulting in their activation. PP405 is being developed as a first-in-class treatment for androgenetic alopecia (pattern hair loss) in men and women, with potential future expansion into chemotherapy-induced alopecia and telogen effluvium. It is delivered as a once-daily topical application with no detectable systemic exposure and is currently an investigational drug in Phase 2a clinical trials (NCT06393452) with Phase 3 studies planned for 2026.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierStrategic Advisor (Cab)TypeImplementation/ SI/ Consulting PartnerAnnounced on2024-08-13
Description

Dr. Mathew Avram, MD, JD, FAAD (Director, MGH Dermatology Laser & Cosmetic Center; Associate Professor of Dermatology, Harvard Medical School) serves on Pelage's Clinical Advisory Board to support clinical development strategy and inclusive trial design.

Strategic tierStrategic Advisor (Cab)TypeImplementation/ SI/ Consulting PartnerAnnounced on2024-08-13
Description

Dr. Arash Mostaghimi, MD, MPA, MPH, FAAD (Vice Chair of Clinical Trials and Innovation, Director of the Dermatology Inpatient Service at Brigham & Women's Hospital; Associate Professor of Dermatology, Harvard Medical School) serves on Pelage's Clinical Advisory Board and presented Phase 2a results at AAD 2026.

Strategic tierStrategic Advisor (Cab)TypeImplementation/ SI/ Consulting PartnerAnnounced on2024-08-13
Description

Dr. Amy McMichael, MD, FAAD (Professor and past Chair, Department of Dermatology at Wake Forest School of Medicine) serves on Pelage's Clinical Advisory Board to advance clinical development.

Strategic tierStrategic Advisor (Cab)TypeImplementation/ SI/ Consulting PartnerAnnounced on2024-08-13
Description

Dr. Amelia K. Hausauer, MD, FAAD (Director of Dermatology and Minimally Invasive Aesthetics at Aesthetx) serves on Pelage's Clinical Advisory Board to support clinical development.

Strategic tierFoundational Scientific Partner / Ip LicensorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

In 2018, Pelage Pharmaceuticals licensed the intellectual property to PP405 and related topical small molecules from the UCLA Technology Development Group. Scientific co-founders Heather Christofk, Ph.D., Michael Jung, Ph.D., and William Lowry, Ph.D. are UCLA researchers whose discovery of a metabolic switch that activates hair follicle stem cells underpins Pelage's technology platform. UCLA Technology Development Group is also referenced in the Terms of Use as a partner.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage regenerative medicine company developing a hair follicle neogenesis approach for androgenetic alopecia; directly comparable to Pelage as a peer biotech targeting hair loss via a stem-cell/regenerative mechanism rather than hormone modulation.

TypeBroad incumbent
Description

Large-cap pharma actively researching hair loss (Eli Lilly's Francisco Ramírez-Valle appeared alongside Pelage's CEO on BioSpace's Denatured podcast to discuss regenerative hair loss innovation); represents a likely strategic acquirer/partner and the dominant incumbent in adjacent immunology/metabolic research.

TypeEmerging player
Description

Clinical-stage dermatology biotech developing topical and small-molecule therapies (e.g., for alopecia areata); comparable business model (clinical-stage dermatology biotech, prescription drug pathway) with adjacent indication focus.

TypeEmerging player
Description

Clinical/specialty dermatology biotech developing topical therapies; similar company stage and topical-prescription model, though focused on different skin conditions — useful comparable for clinical execution and commercial readiness.

TypeEmerging player
Description

Commercial-stage genetic medicines biotech with a topical/repeat-dosing platform and dermatology indication (Vyjuvek); comparable as a small-cap dermatology biotech with a novel topical mechanism and FDA approval, providing a useful valuation and launch benchmark.

6Botanix Pharmaceuticals
TypeEmerging player
Description

Clinical-stage dermatology biotech developing topical cannabinoid-based therapies for skin conditions; comparable as a small-cap, clinical-stage, topical-prescription dermatology peer and potential M&A/partner candidate.

TypeDirect peer
Description

Pre-clinical/early-stage biotech using iPSC-derived hair follicle stem cells to regenerate hair; operates in the same regenerative hair-loss category as Pelage and represents the most direct scientific peer for the HFSC activation thesis.

8Cassiopea (Cosmo Pharmaceuticals subsidiary)
TypeEmerging player
Description

Developed clascoterone (Winlevi) for androgen-driven dermatology indications; comparable as a late-stage dermatology biotech with a prescription/topical model and FDA-approved asset, providing a relevant commercialization benchmark for Pelage.

TypeBroad incumbent
Description

Markets Rogaine (minoxidil), the leading OTC hair loss treatment, and operates a large dermatology franchise through Janssen; relevant incumbent peer for both competitive dynamics and potential partnership/acquisition scenarios.

TypeBroad incumbent
Description

Consumer telehealth platform (including Keeps) prescribing finasteride/minoxidil and other hair loss treatments at scale; represents the dominant direct-to-consumer commercialization channel for hair loss and a likely distribution/partner pathway for any approved prescription product.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pelage Pharmaceuticals

Regenerative Hair Loss Therapeuticspelagepharma.com

Pelage Pharmaceuticals is a clinical-stage regenerative medicine biotech developing PP405, a topical small-molecule MPC inhibitor that reactivates dormant hair follicle stem cells, for men and women with androgenetic alopecia and related forms of hair loss.

What Pelage Pharmaceuticals does

Pelage Pharmaceuticals, Inc. is a privately held, clinical-stage regenerative medicine biotechnology company founded in 2018 and headquartered in Los Angeles, California. The company is developing PP405, a topical small-molecule mitochondrial pyruvate carrier (MPC) inhibitor designed to reactivate dormant hair follicle stem cells (HFSCs) by inhibiting pyruvate oxidation and upregulating lactate dehydrogenase (LDH), thereby restoring the natural hair follicle growth cycle. The technology is rooted in a metabolic switch discovery made by UCLA scientists and is exclusively licensed from the UCLA Technology Development Group.

The company's lead clinical program targets androgenetic alopecia (pattern hair loss), with potential pipeline expansion into chemotherapy-induced alopecia and telogen effluvium. PP405 has completed a Phase 2a randomized placebo-controlled trial in 78 men and women with androgenetic alopecia, meeting its primary safety endpoint with no systemic absorption detected in blood; 31% of men with higher hair loss achieved a >20% increase in hair density at Week 8 versus 0% on placebo, and the program is advancing into Phase 3 trials planned for 2026. The trial design and intended label are explicitly inclusive, targeting all genders, skin phototypes, and hair types.

Pelage is pre-revenue and funded by venture capital, having raised approximately $150.75 million across a Series A (Feb 2024), Series A-1 (Aug 2024), and Series B (Oct 2025), with the Series B co-led by ARCH Venture Partners and GV (Google Ventures). The business model anticipates future revenue from FDA-approved prescription drug commercialization via direct physician-targeted sales or licensing/partnership with a larger pharmaceutical company. Leadership includes a scientific founding team from UCLA, a Clinical Advisory Board of leading academic dermatologists, and an investor-anchored board with deep biotech operating and capital markets experience.

Pelage Pharmaceuticals firmographics

Firmographics
Name
Pelage Pharmaceuticals
Legal name
Pelage Pharmaceuticals, Inc.
Website
https://pelagepharma.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Pelage Pharmaceuticals is a clinical-stage regenerative medicine biotech developing PP405, a topical small-molecule MPC inhibitor that reactivates dormant hair follicle stem cells, for men and women with androgenetic alopecia and related forms of hair loss.
Ownership category
akta.pro rank

Pelage Pharmaceuticals industry classification

Industry
Product category
Regenerative Hair Loss Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Regenerative medicine biotechnology
  • Hair loss therapeutics
  • Topical small molecule
  • Stem cell activation
  • Clinical-stage drug development

Where Pelage Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pelage Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Pre-revenue clinical-stage drug development: Currently pre-revenue; the company is a clinical-stage biotech developing its lead asset PP405 through Phase 2a with Phase 3 trials planned for 2026. No commercial product on market. Future revenue expected from FDA-approved prescription drug commercialization (direct sales or partnership licensing).
  2. Equity financing (venture capital): Funded through successive venture capital rounds: $16.75M Series A (Feb 2024), $14M Series A-1 (Aug 2024), and $120M Series B (Oct 2025) — totaling approximately $150.75M raised from GV (Google Ventures), ARCH Venture Partners, Main Street Advisors, Visionary Ventures, and YK Bioventures.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goInvestigational drug — no commercial pricing available

Go-to-market motion3 records

Distribution channels1 record

Marketing channels8 records

Pelage Pharmaceuticals product offering

Product offering

Core offering

Pelage Pharmaceuticals is developing PP405, a novel, non-invasive, topical small-molecule drug that acts as a mitochondrial pyruvate carrier (MPC) inhibitor to reactivate dormant hair follicle stem cells and stimulate hair regrowth. The investigational product is being advanced through FDA-regulated clinical trials as a first-in-class regenerative treatment for androgenetic alopecia (pattern hair loss), with potential expansion into chemotherapy-induced alopecia and telogen effluvium. The company is currently pre-revenue, with Phase 2a complete and Phase 3 trials planned for 2026, and intends to commercialize via direct physician-targeted sales or partnership with a larger pharmaceutical company.

Product overview

Pelage Pharmaceuticals is a clinical-stage regenerative medicine biotechnology company offering a single unified investigational product platform centered on its lead program PP405. The PP405 platform is a non-invasive, topical small molecule drug designed to reactivate dormant hair follicle stem cells and restore the body's natural ability to grow hair. PP405 acts as a mitochondrial pyruvate carrier (MPC) inhibitor, upregulating lactate dehydrogenase (LDH) to drive stem cell activation and follicular regeneration. It is being developed as a first-in-class treatment for androgenetic alopecia (pattern hair loss) and potentially other forms of hair loss including drug-induced alopecia and telogen effluvium. The technology is rooted in pioneering stem cell research out of UCLA (licensed in 2018) and is delivered as a once-daily topical application without detectable systemic exposure. Pelage is currently advancing PP405 through Phase 2a clinical trials with plans to initiate Phase 3 studies in 2026. The product is targeted at men and women of all skin types and hair types.

Differentiator

Problem solved

Functional benefit

Brands

  • PP405: Pelage's lead investigational product: a novel, non-invasive, topical small molecule (mitochondrial pyruvate carrier / MPC inhibitor) designed to reactivate dormant hair follicle stem cells and restart hair growth in androgenetic alopecia and other forms of alopecia.

Products and services

  • PP405 PP405 is a novel, non-invasive, topical small-molecule drug (mitochondrial pyruvate carrier / MPC inhibitor) designed to reactivate dormant hair follicle stem cells and restart hair growth. It acts on the cellular metabolic pathway to upregulate lactate dehydrogenase (LDH), which stem cells are particularly sensitive to, resulting in their activation. PP405 is being developed as a first-in-class treatment for androgenetic alopecia (pattern hair loss) in men and women, with potential future expansion into chemotherapy-induced alopecia and telogen effluvium. It is delivered as a once-daily topical application with no detectable systemic exposure and is currently an investigational drug in Phase 2a clinical trials (NCT06393452) with Phase 3 studies planned for 2026.

Quantifiable outcome

  • 31% of men with higher hair loss achieved >20% increase in hair density at Week 8 (vs. 0% in placebo group) after only 4 weeks of topical PP405 dosing
  • +3 more outcomes

Companies that use Pelage Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles2 records

Pelage Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Pelage Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered strategic advisor (cab) and foundational scientific partner / ip licensor.

  • Massachusetts General Hospital / Harvard Medical School (Clinical Advisory Board)strategic advisor (cab)Implementation/ SI/ Consulting Partner · 13 August 2024Dr. Mathew Avram, MD, JD, FAAD (Director, MGH Dermatology Laser & Cosmetic Center; Associate Professor of Dermatology, Harvard Medical School) serves on Pelage's Clinical Advisory Board to support clinical development strategy and inclusive trial design.
  • Brigham and Women's Hospital / Harvard Medical School (Clinical Advisory Board)strategic advisor (cab)Implementation/ SI/ Consulting Partner · 13 August 2024Dr. Arash Mostaghimi, MD, MPA, MPH, FAAD (Vice Chair of Clinical Trials and Innovation, Director of the Dermatology Inpatient Service at Brigham & Women's Hospital; Associate Professor of Dermatology, Harvard Medical School) serves on Pelage's Clinical Advisory Board and presented Phase 2a results at AAD 2026.
  • Wake Forest School of Medicine (Clinical Advisory Board)strategic advisor (cab)Implementation/ SI/ Consulting Partner · 13 August 2024Dr. Amy McMichael, MD, FAAD (Professor and past Chair, Department of Dermatology at Wake Forest School of Medicine) serves on Pelage's Clinical Advisory Board to advance clinical development.
  • Aesthetx (Clinical Advisory Board)strategic advisor (cab)Implementation/ SI/ Consulting Partner · 13 August 2024Dr. Amelia K. Hausauer, MD, FAAD (Director of Dermatology and Minimally Invasive Aesthetics at Aesthetx) serves on Pelage's Clinical Advisory Board to support clinical development.
  • University of California, Los Angeles (UCLA) — UCLA Technology Development Groupfoundational scientific partner / ip licensorStrategic or Co-development Partner · 1 January 2018In 2018, Pelage Pharmaceuticals licensed the intellectual property to PP405 and related topical small molecules from the UCLA Technology Development Group. Scientific co-founders Heather Christofk, Ph.D., Michael Jung, Ph.D., and William Lowry, Ph.D. are UCLA researchers whose discovery of a metabolic switch that activates hair follicle stem cells underpins Pelage's technology platform. UCLA Technology Development Group is also referenced in the Terms of Use as a partner.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Pelage Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Follica: Clinical-stage regenerative medicine company developing a hair follicle neogenesis approach for androgenetic alopecia; directly comparable to Pelage as a peer biotech targeting hair loss via a stem-cell/regenerative mechanism rather than hormone modulation.
  • Stemson Therapeutics: Pre-clinical/early-stage biotech using iPSC-derived hair follicle stem cells to regenerate hair; operates in the same regenerative hair-loss category as Pelage and represents the most direct scientific peer for the HFSC activation thesis.

Broad incumbents

  • Eli Lilly: Large-cap pharma actively researching hair loss (Eli Lilly's Francisco Ramírez-Valle appeared alongside Pelage's CEO on BioSpace's Denatured podcast to discuss regenerative hair loss innovation); represents a likely strategic acquirer/partner and the dominant incumbent in adjacent immunology/metabolic research.
  • Johnson & Johnson: Markets Rogaine (minoxidil), the leading OTC hair loss treatment, and operates a large dermatology franchise through Janssen; relevant incumbent peer for both competitive dynamics and potential partnership/acquisition scenarios.
  • Hims & Hers Health: Consumer telehealth platform (including Keeps) prescribing finasteride/minoxidil and other hair loss treatments at scale; represents the dominant direct-to-consumer commercialization channel for hair loss and a likely distribution/partner pathway for any approved prescription product.

Emerging players

  • Aclaris Therapeutics: Clinical-stage dermatology biotech developing topical and small-molecule therapies (e.g., for alopecia areata); comparable business model (clinical-stage dermatology biotech, prescription drug pathway) with adjacent indication focus.
  • Verrica Pharmaceuticals: Clinical/specialty dermatology biotech developing topical therapies; similar company stage and topical-prescription model, though focused on different skin conditions — useful comparable for clinical execution and commercial readiness.
  • Krystal Biotech: Commercial-stage genetic medicines biotech with a topical/repeat-dosing platform and dermatology indication (Vyjuvek); comparable as a small-cap dermatology biotech with a novel topical mechanism and FDA approval, providing a useful valuation and launch benchmark.
  • Botanix Pharmaceuticals: Clinical-stage dermatology biotech developing topical cannabinoid-based therapies for skin conditions; comparable as a small-cap, clinical-stage, topical-prescription dermatology peer and potential M&A/partner candidate.
  • Cassiopea (Cosmo Pharmaceuticals subsidiary): Developed clascoterone (Winlevi) for androgen-driven dermatology indications; comparable as a late-stage dermatology biotech with a prescription/topical model and FDA-approved asset, providing a relevant commercialization benchmark for Pelage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights4 records

Customer concentration

Pelage Pharmaceuticals social profiles

Digital presence

Pelage Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pelage Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles20 records

Pelage Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pelage Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pelage Pharmaceuticals

What does Pelage Pharmaceuticals do?

Pelage Pharmaceuticals is developing PP405, a novel, non-invasive, topical small-molecule drug that acts as a mitochondrial pyruvate carrier (MPC) inhibitor to reactivate dormant hair follicle stem cells and stimulate hair regrowth. The investigational product is being advanced through FDA-regulated clinical trials as a first-in-class regenerative treatment for androgenetic alopecia (pattern hair loss), with potential expansion into chemotherapy-induced alopecia and telogen effluvium. The company is currently pre-revenue, with Phase 2a complete and Phase 3 trials planned for 2026, and intends to commercialize via direct physician-targeted sales or partnership with a larger pharmaceutical company.

Is Pelage Pharmaceuticals a public or private company?

Pelage Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pelage Pharmaceuticals founded?

Pelage Pharmaceuticals was founded in 2018. It employs 11 to 50 people.

Where is Pelage Pharmaceuticals based?

Pelage Pharmaceuticals is headquartered in Los Angeles, United States, in the North America region.

How does Pelage Pharmaceuticals make money?

Two revenue lines are on record. Pre-revenue clinical-stage drug development is the primary driver. The others are equity financing (venture capital).

Who are Pelage Pharmaceuticals's main competitors?

Direct peers on record are Follica and Stemson Therapeutics. Broad incumbents are Eli Lilly, Johnson & Johnson and Hims & Hers Health. Emerging players are Aclaris Therapeutics, Verrica Pharmaceuticals, Krystal Biotech, Botanix Pharmaceuticals and Cassiopea (Cosmo Pharmaceuticals subsidiary).

Does Pelage Pharmaceuticals have an API?

No public API is recorded for Pelage Pharmaceuticals.

What industry is Pelage Pharmaceuticals in?

Pelage Pharmaceuticals's product category is Regenerative Hair Loss Therapeutics. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIAAAM, Nephrology & Urology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireIndero Supports Pelage Pharmaceuticals on its Growing Clinical Program for Hair LossPelage Pharmaceuticals, with Indero's support, is advancing PP405 into late-stage development after its Phase 2a trial met the primary endpoint and showed rapid hair growth in men. The company plans a 12-month AWAKEN study in men and a Phase 2 trial for women later this year.EIN PresswireIndero Supports Pelage Pharmaceuticals on its Growing Clinical Program for Hair LossPelage Pharmaceuticals, with Indero's support, is advancing PP405 into late-stage development for androgenetic alopecia. The Phase 2a trial met its primary endpoint, showing PP405 was well tolerated with no systemic absorption, and a Phase 2a study in women is planned later this year.Business Wire BlogPelage Pharmaceuticals Announces First Patient Dosed in Phase 2/3 AWAKEN Trial of PP405 for Androgenetic Alopecia, the Most Common Form of Hair LossPelage Pharmaceuticals announced the first patient dosed in the Phase 2/3 AWAKEN trial of PP405 for androgenetic alopecia in men. The trial follows positive Phase 2a results showing new hair growth and a strong safety profile. A Phase 2 trial in women is planned by end of 2026.Robb ReportAre Hair Transplants Getting Replaced By a New Class of Regenerative Treatments?Pelage Pharmaceuticals' PP405, a metabolic hair-loss treatment, has shown in trials that it regrows thick, pigmented hair in previously bare patches. The company has raised over $150 million since 2024, but FDA approval is years away. Hair-transplant demand remains high, with patient loads up 20% since 2021.Dermatology TimesTop 5 Articles of the Week: May 18-23This article is a weekly roundup of five distinct dermatology news items, including clinical trial updates from Pelage Pharmaceuticals and Eirion Therapeutics, a UCLA study on psoriasis treatments, an AI platform by MDAlgorithms, and new guidelines from Arcutis Biotherapeutics. The reports cover various developments in hair loss and skin condition treatments without focusing on a single corporate event or financial transaction. As a curated list of multiple unrelated stories, it does not represent a singular market-moving event.BioSpaceRethinking hair loss treatmentBioSpace's podcast Denatured features a discussion with Daniel Gil, CEO of Pelage Pharmaceuticals, and Francisco Ramírez-Valle, Senior Vice President of Immunology Discovery at Eli Lilly, exploring the hair loss treatment space and why innovation has lagged in this area. The executives discuss a regenerative approach aimed at reactivating dormant hair follicles and what early proof-of-concept data could mean for patients.Labiotech.euTreating pattern hair loss: how close are we?VeraDermics' VDPHL01, an oral minoxidil pill, met primary endpoints in a phase 2/3 trial, showing robust hair growth in men. The drug is expected to be the first new FDA-approved treatment for pattern hair loss in nearly 30 years, with a female trial ongoing and top-line results anticipated later this year.openPR.comLaser Hair Loss Treatment Market (2026) | How Are Dermatology Clinics Adopting Laser Hair Regrowth Technologies?DataM Intelligence published a market research report on the global laser hair loss treatment market, projecting a 12.0% CAGR during 2024–2031, with North America accounting for 48.5% of revenue. The report documents significant M&A and funding activity across the sector, including Henkel's $1.4 billion acquisition of OLAPLEX and Pelage Pharmaceuticals securing $120 million in funding for its regenerative hair loss therapy. Multiple companies — including Capillus, Lumenis, Lexington International, and Bosley Medical Group — advanced their laser and AI-integrated hair regrowth device portfolios, while firms in Japan such as Aderans, Panasonic Holdings, and Shiseido developed new scalp laser and red-light therapy products.UCLA Samueli School of Engineering. Engineer Change.When Chemistry and Biochemistry Meet the Marketplace – UCLAUCLA's Division of Physical Sciences has developed a robust culture of entrepreneurship among its chemistry and biochemistry researchers, with faculty founding multiple companies that have successfully commercialized academic research into real-world products and services. Key successes include Silq Technologies (FDA-cleared medical device coating), eXoZymes (went public in 2024), Generation Genius (acquired by Newsela for $100 million in February 2025), and Pelage Pharmaceuticals (attracting investment from Google Ventures and Arch Venture Partners for a Phase 3 clinical trial hair regeneration treatment). The department's transformation, supported by Associate Dean Mike Jung and Dean Miguel García-Garibay, demonstrates how academic scientific research can be systematically translated into commercial ventures with significant societal impact.Men's HealthNew Men's Hair Loss Treatments in 2026: What Works for RegrowthScientists at Pelage Pharmaceuticals and Veradermics presented new hair loss treatment candidates at the American Academy of Dermatology annual meeting in Denver, both currently in clinical trial phases. Pelage's PP405 molecule targets dormant hair follicles with Phase 2a data showing 31% of subjects achieving over 20% hair density increase versus 0% for placebo, while Veradermics' extended-release oral minoxidil VDPHL01 demonstrated visible improvement at two months compared to six months for existing formulations. Neither treatment is yet available to patients and may require a year or more before receiving regulatory approval.